RxDoctor Payments Data

Pamela Green, APRN

Acute Care · Paducah, KYNPI 1134291743

Payments from drug & device makers

$919in general payments, 2019–2025

Across 71 payments — averaging $12.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$349
  • AbbVie$89
  • Amgen$85
  • Lilly USA, LLC$69
  • Exact Sciences$55
  • Astellas Pharma US Inc$52
  • plus $220 from 12 others

What the payments were for

  • Food & beverage$919100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$919 in reported general payments places this provider in the 70th percentile of 319 acute care providers in Kentucky.

See all acute care providers in Kentucky

Medicare billing

Part B allowed, 2024
$54,387
Medicare patients
260
Services billed
2,831

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide67$89,584
EliquisApixaban71$57,374
JanuviaSitagliptin Phosphate46$57,274
JardianceEmpagliflozin46$40,418
XareltoRivaroxaban28$34,640
MyrbetriqMirabegron12$13,275
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$11,498
MounjaroTirzepatide11$11,348
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$10,796
EntrestoSacubitril/Valsartan11$7,277
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$3,948
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen150$3,276
Humalog Kwikpen U-100Insulin Lispro11$3,226
ShingrixVaricella-Zoster Ge/As01b/Pf15$3,105
Novolog FlexpenInsulin Aspart13$3,082

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$349$89,58467 claims
Boehringer IngelheimJardiance$14$40,41846 claims
Astellas Pharma US IncMyrbetriq$52$13,27512 claims
Lilly USA, LLCMounjaro$69$11,34811 claims
GSKShingrix$23$3,10515 claims
AbbVieSynthroid$89$2,23960 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 319 acute care providers in Kentucky.

Other acute care in Paducah

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →